Fig. 1
Clinical course of rhabdomyolysis and NSCLC. Reduced doses of dabrafenib and trametinib combination treatment prevented the incidence of rhabdomyolysis and tumor progression
Fig. 1 | BMC Cancer
Clinical course of rhabdomyolysis and NSCLC. Reduced doses of dabrafenib and trametinib combination treatment prevented the incidence of rhabdomyolysis and tumor progression